A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.

Abstract	Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM.
Authors	Mark V Sherrid, Milla Arabadjian
Journal	Progress in cardiovascular diseases (Prog Cardiovasc Dis) 2012 May-Jun Vol. 54 Issue 6 Pg. 483-92 ISSN: 1873-1740 [Electronic] United States
PMID	22687589 (Publication Type: Journal Article, Review)
Copyright	Copyright © 2012 Elsevier Inc. All rights reserved.
Chemical References	Anti-Arrhythmia Agents Disopyramide
Topics	Anti-Arrhythmia Agents (therapeutic use) Cardiomyopathy, Hypertrophic (drug therapy, etiology) Disopyramide (therapeutic use) Heart Failure (prevention & control) Humans Ventricular Outflow Obstruction (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!